TickerSpark Feed

life sciences

Everything tagged "life sciences" across the TickerSpark archives.

Agilent Technologies (A): Replacement Cycle Momentum Builds

Agilent posted 6.3% core growth, 14% EPS growth, and raised FY26 guidance, but the stock still needs continued execution at 23.0x forward earnings.

Aug 26, 2026·20 MIN

Healthcare Diagnostics & Research Growth

Research ReportWAT

Waters Corporation (WAT): BD Deal Fuels Growth, Raises Risk

Waters is leaning into a larger life-science and diagnostics platform after its BD Biosciences and Diagnostic Solutions acquisition. Strong Q1 growth and raised guidance support a Buy, but leverage and a premium valuation keep the setup balanced.

Aug 4, 2026·19 MIN

Healthcare Diagnostics & Research Healthcare

Research ReportIQV

IQVIA Holdings (IQV): AI Data Scale Drives Growth

IQVIA is pairing healthcare data scale with accelerating Commercial Solutions growth and a record R&D backlog. The stock looks attractive for investors who can accept leverage in exchange for durable life sciences exposure.

Jul 28, 2026·19 MIN

Healthcare Diagnostics & Research AI

Research ReportTMO

Thermo Fisher Scientific (TMO): Buy on Pullbacks

Thermo Fisher remains a scaled, resilient life sciences compounder with strong cash generation and raised 2026 guidance. The stock looks attractive on quality, but valuation and leverage argue for patience rather than chasing it higher.

Jul 23, 2026·19 MIN

Healthcare Diagnostics & Research Healthcare

Research ReportDHR

Danaher (DHR): Improving Growth, Rich Valuation

Danaher is seeing better operating momentum across Life Sciences, Diagnostics, and Biotechnology, but the stock still trades at a premium that limits upside. The report keeps a Buy rating with fair value set at $225.

Jul 22, 2026·21 MIN

Healthcare Diagnostics & Research Healthcare

Research ReportRVTY

Revvity (RVTY): Recovery Story With Software Upside

Revvity is a balanced life sciences and diagnostics operator with improving earnings, solid cash flow, and a growing software mix. The stock looks more like a recovery rerating than a breakout, but valuation is reasonable if forward EPS delivers.